featured
SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Gastroenterology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis
Gastroenterology 2020 Aug 04;[EPub Ahead of Print], MR Henn, EJ O'Brien, L Diao, BG Feagan, WJ Sandborn, C Huttenhower, JR Wortman, BH McGovern, S Wang-Weigand, DI Lichter, M Chafee, CB Ford, P Bernardo, P Zhao, S Simmons, A Tomlinson, D Cook, R Pomerantz, BK Misra, JG Auninš, M TrucksisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.